|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-7-29
|
|
pubmed:abstractText |
To determine the maximum tolerated doses (MTDs) and dose limiting toxicities (DLTs) of gemcitabine (GEM), docetaxel (DOC) and carboplatin (CARBO) combination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
785-91
|
|
pubmed:meshHeading |
pubmed-meshheading:19159931-Adult,
pubmed-meshheading:19159931-Aged,
pubmed-meshheading:19159931-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19159931-Breast Neoplasms,
pubmed-meshheading:19159931-Carboplatin,
pubmed-meshheading:19159931-Deoxycytidine,
pubmed-meshheading:19159931-Female,
pubmed-meshheading:19159931-Humans,
pubmed-meshheading:19159931-Maximum Tolerated Dose,
pubmed-meshheading:19159931-Middle Aged,
pubmed-meshheading:19159931-Taxoids
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
